Trial Profile
A Phase II Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jun 2022
Price :
$35
*
At a glance
- Drugs Lanreotide (Primary)
- Indications Fistula
- Focus Therapeutic Use
- 22 May 2022 Status changed from active, no longer recruiting to completed.
- 17 Mar 2021 Planned End Date changed from 1 May 2021 to 1 Apr 2021.
- 17 Mar 2021 Status changed from recruiting to active, no longer recruiting.